Tiziana Life Sciences Ltd (TLSA) Form 6-K — Aug 24, 2026
Tiziana Life Sciences (Nasdaq: TLSA) announced that a poster on its Phase 2a BANYAN trial of intranasal foralumab in ALS, titled 'Phase 2a Trial of Intranasal Foralumab - BANYAN, a Healey ALS MyMatch Trial,' was presented by Dr. Pinar Uysal at the ALS Nexus 2026 conference in Orlando on August 24, 2026. BANYAN is a 3:1 randomized, placebo-controlled, multicenter Phase 2a study running across NEALS sites on the Healey ALS MyMatch infrastructure at Mass General Brigham, designed to assess safety, immune-modulation biomarkers including PET imaging of microglial activation, and early signals of clinical effect in ALS patients.
Key figures
- Trial phase
- Phase 2a
- Conference dates
- August 23-26, 2026
- Poster session time
- 4:30-6:30 p.m. ET, August 24, 2026
- Banyan randomization ratio
- 3:1 (foralumab:placebo)
- Expanded access efficacy note
- improvement or stability of disease within 6 months in all 14 na-SPMS patients
- Expanded access patients dosed
- 14
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.